-- 
XTL Biopharmaceuticals Soars Most Since March on FDA Status

-- B y   G w e n   A c k e r m a n
-- 
2011-05-29T14:10:56Z

-- http://www.bloomberg.com/news/2011-05-29/xtl-biopharmaceuticals-soars-most-since-march-on-fda-status-1-.html
XTL Biopharmaceuticals Ltd. (XTLB)  climbed
the most in two months after the U.S.  Food and Drug
Administration  granted the pharmaceutical developerâ€™s myeloma
treatment orphan drug status.  The shares soared 17 percent, the most since March 28, to
0.609 shekel at the 4:30 p.m. close in Tel Aviv, giving the Nes
Ziona, Israel-based company a market value of 124.3 million
shekels ($35.8 million).  To contact the reporter on this story:
Gwen Ackerman in Jerusalem at 
 gackerman@bloomberg.net   To contact the editor responsible for this story:
Susan Lerner at 
 slerner2@bloomberg.net  